Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRW4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, awarded on January 29, 2026, with an ultimate completion date of February 20, 2026, carries no set-aside designation, indicating the vendor competed in the open market against other qualified suppliers. The order was placed under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to consolidate pharmaceutical supply across the Department of Defense.
DMS Pharmaceutical Group maintains a substantial $499,999,999 ceiling value contract under the PPV-G GEN V program, which runs through December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for military healthcare facilities worldwide. The vendor's extensive product portfolio encompasses branded and generic pharmaceuticals, biologics, specialty drugs, and medical consumables, with demonstrated performance across numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. This particular delivery order for Stelara, an immunosuppressant biologic used to treat conditions such as psoriasis and inflammatory bowel disease, reflects the company's role in supporting the recurring pharmaceutical needs of Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRW4?
SPE2DR26FCRW4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FCRW4 worth?
The government has obligated $16,584 on SPE2DR26FCRW4.
Is contract SPE2DR26FCRW4 an order under another contract?
Yes. SPE2DR26FCRW4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRW4 competed?
The extent of competition for SPE2DR26FCRW4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award